Merck & Co., Inc. vs Western Digital Corp — how do they compare? Merck & Co., Inc. trades at $132.9 (market cap $321.77B), while Western Digital Corp trades at $456.37 (market cap $150.95B). The key difference: Merck & Co., Inc. is far larger — about 2.1× Western Digital Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MRK | WDC | |
|---|---|---|
Market Cap | $321.77B | $150.95B |
Sector | Health | Technology |
52-Week High | $131.84 | $746.23 |
52-Week Low | $77.60 | $74.66 |
Enterprise Value | $368.53B | $150.42B |
Dividend Yield | 2.61% | 0.14% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Western Digital (WDC) trades at $454.50, up 3.74% in the last session, with a bearish technical signal but strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $3.56 versus $3.31 expected, highlight robust AI-driven storage demand. The stock is near resistance at $458, with a consensus analyst price target of $665.15 suggesting significant upside potential.
Outlook is positive due to sustained AI infrastructure growth and margin expansion, but risks include valuation concerns and competitive threats. Analyst consensus is strongly bullish with 72% buy ratings, though technical indicators signal near-term caution. Investors should weigh strong earnings momentum against potential volatility from stretched valuations.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →